D000986Chemicals & DrugsD27.505.954.502.135440.998536Antisickling Agentsprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson0.2175870.01006664research area of0.8716250.04032534subject area for29419425Boulad F, Shore T, van Besien K, Minniti C, Barbu-Stevanovic M, Fedus SW, Perna F, Greenberg J, Guarneri D, Nandi V, Mauguen A, Yazdanbakhsh K, Sadelain M, Shi PAHaematologicaSafety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results. Haematologica. 2018 05; 103(5):770-777.Haematologica2018-02-01T00:00:002018Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results.JaneHollJane Holl41.7886000000000087.598699999999993877Holl, JaneProfessorKoenVan BesienKoen Van Besien0.000000000000000.000000000000002944Van Besien, KoenPROFESSOR271972Walder JA, Zaugg RH, Iwaoka RS, Watkin WG, Klotz IMProceedings of the National Academy of Sciences of the United States of AmericaAlternative aspirins as antisickling agents: acetyl-3,5-dibromosalicylic acid. Proc Natl Acad Sci U S A. 1977 Dec; 74(12):5499-503.Proc Natl Acad Sci U S A1977-12-01T00:00:001977Alternative aspirins as antisickling agents: acetyl-3,5-dibromosalicylic acid.35373884Creary SE, Beeman C, Stanek J, King K, McGann PT, O'Brien SH, Liem RI, Holl J, Badawy SMPediatric blood & cancerImpact of hydroxyurea dose and adherence on hematologic outcomes for children with sickle cell anemia. Pediatr Blood Cancer. 2022 06; 69(6):e29607.Pediatr Blood Cancer2022-04-04T00:00:002022Impact of hydroxyurea dose and adherence on hematologic outcomes for children with sickle cell anemia.MedicineNeurologyPathologyUniversity of ChicagoWilliamWatkinWilliam Watkin41.78927490000000-87.601250000000002523Watkin, WilliamClinical Assistant ProfessorChad ThomasWhelanChad Thomas Whelan41.78927490000000-87.60125000000000903Whelan, Chad ThomasAssociate Professortrue1PROFESSORPROFESSORtrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1Clinical Assistant ProfessorClinical Assistant Professor21141288Artz N, Whelan C, Feehan SJournal of the National Medical AssociationCaring for the adult with sickle cell disease: results of a multidisciplinary pilot program. J Natl Med Assoc. 2010 Nov; 102(11):1009-16.J Natl Med Assoc2010-11-01T00:00:002010Caring for the adult with sickle cell disease: results of a multidisciplinary pilot program.